menu
    • menu

    Company profile for Veradermics

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Willow Birch Pharma delivers trusted, high-quality APIs nationwide with unmatched service, compliance, and competitive value.

    Virtual Booth

    Contact Supplier

    AMI Lifesciences is Driven by Chemistry. Powered by People.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Veradermics is a pioneering biotechnology company dedicated to advancing dermatology through innovative treatments. With a robust pipeline of five novel product candidates, Veradermics addresses large-market conditions such as androgenetic alopecia (pattern hair loss), common warts, molluscum contagiosum, alopecia areata, and atopic dermatitis. Our mission is to bring transformative therapies to adults and children, focusing o...
    Veradermics is a pioneering biotechnology company dedicated to advancing dermatology through innovative treatments. With a robust pipeline of five novel product candidates, Veradermics addresses large-market conditions such as androgenetic alopecia (pattern hair loss), common warts, molluscum contagiosum, alopecia areata, and atopic dermatitis. Our mission is to bring transformative therapies to adults and children, focusing on conditions that have long been underserved by existing treatment options. Driven by science and patient needs, Veradermics aims to redefine dermatological care with safe, effective, and accessible solutions.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    VeradermicsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    470 James St New Haven, CT 06513
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.veradermics.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Veradermics Advances VDPHL01 Trial For Male Pattern Hair Loss
    Veradermics Advances VDPHL01 Trial For Male Pattern Hair Loss

    11 Dec 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251211386584/en/Veradermics-Completes-Enrollment-in-its-Phase-23-Clinical-Trial-of-VDPHL01-for-Male-Pattern-Hair-Loss-Advancing-Development-of-the-Potential-First-Ever-Extended-Release-Oral-Minoxidil

    BUSINESSWIRE
    11 Dec 2025
    Share Share
    Veradermics VDPHL01 Enters Phase 2/3 for Female Pattern Hair Loss
    Veradermics VDPHL01 Enters Phase 2/3 for Female Pattern Hair Loss

    18 Nov 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251118317254/en/Veradermics-Advances-VDPHL01-in-Phase-23-Clinical-Trial-for-Female-Pattern-Hair-Loss-Marking-a-Milestone-in-the-Development-of-the-Potential-First-Ever-Oral-Prescription-Treatment-for-Women

    BUSINESSWIRE
    18 Nov 2025
    Share Share
    Veradermics Secures $150M For VDPHL01 Phase 3 Trials In Hair
    Veradermics Secures $150M For VDPHL01 Phase 3 Trials In Hair

    16 Oct 2025

    // BUSINESS WIRE

    https://www.businesswire.com/news/home/20251016863981/en/Veradermics-Announces-Oversubscribed-%24150-Million-Series-C-Financing-to-Advance-VDPHL01-Through-Multiple-Phase-3-Trials-as-Potentially-the-First-Non-Hormonal-Oral-Therapeutic-for-Hair-Regrowth-in-Women-and-Men

    BUSINESS WIRE
    16 Oct 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search